FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound selected from the group consisting of:
;
;
; 
;
;
;
; and its pharmaceutically acceptable salts and solvates. Also disclosed are a pharmaceutical composition, use of the compound or a pharmaceutically acceptable salt or solvate thereof for preparing a medicinal agent and a method of treating a disease or condition, involving plasma kallikrein activity.
EFFECT: disclosed compound is a plasma kallikrein inhibitor and has a number of therapeutic applications, in particular in treating the vascular permeability associated with diabetic retinopathy and diabetic macular edema.
27 cl, 17 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDE COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | 2015 |
|
RU2707870C2 |
| N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDE COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | 2015 |
|
RU2821520C2 |
| POLYMORPHIC MODIFICATIONS OF N-[(3-FLUORO-4-METHOXYPYRIDINE-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({ 4-[(2-OXOPYRIDINE-1-YL)METHYL]PHENYL} METHYL)PYRAZOLE-4-CARBOXAMIDE AND THEIR SALTS | 2017 |
|
RU2756273C2 |
| ENZYME INHIBITORS | 2014 |
|
RU2674028C2 |
| BICYCLIC DIHYDROPYRIMIDINECARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | 2017 |
|
RU2778478C2 |
| 2-(PHENYL OR PYRID-3-YL)AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF LEUCINE-RICH REPEATING KINASE 2 (LRRK2) FOR TREATMENT OF PARKINSON'S DISEASE | 2012 |
|
RU2647849C2 |
| SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | 2014 |
|
RU2802185C2 |
| 2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2005 |
|
RU2417990C2 |
| PHARMACEUTICALLY ACTIVE COMPOUNDS AS Axl INHIBITORS | 2011 |
|
RU2573834C2 |
| BENZYLAMINE DERIVATIVES | 2014 |
|
RU2660421C2 |
